natgillin/translations-raw huggingface dataset:
Pharmacokinetic, biodistribution and dosimetry data were obtained in 6 patients at an activity of 110 kBq/kg given twice, 6 weeks apart, and in 10 patients at an activity of 55, 110 or 221 kBq/kg.
Farmakokinetički, biodistribucijski i dozimetrijski podaci dobiveni su od 6 bolesnika za aktivnost od 110 kBq/kg primijenjenu dvaput u razmaku od 6 tjedana te od 10 bolesnika za aktivnost od 50, 100 ili 221 kBq/kg.
Pharmacokinetic/pharmacodynamic (PK/PD) relationship
Farmakokinetički/farmakodinamički (PK/PD) odnos
Pharmacokinetic/Pharmacodynamic (PK/PD) relationship:
Farmakokinetički/farmakodinamički (PK/PD) odnos:
Pharmacokinetic/pharmacodynamic relationship:
Odnos farmakokinetike/farmakodinamike:
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the (CSF) levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 µmol in human frontal cortex.
Farmakokinetički/farmakodinamički odnos: pri dozi od 20 mg memantina dnevno razine u CSL-u odgovaraju ki-vrijednosti (ki = konstanta inhibicije) memantina koja u frontalnom korteksu kod ljudi iznosi 0,5 µmol.
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 µmol in human frontal cortex.
Farmakokinetički/farmakodinamički odnos: pri dozi od 20 mg memantina dnevno razine u CSL-u odgovaraju ki-vrijednosti (ki = konstanta inhibicije) memantina koja u frontalnom korteksu kod ljudi iznosi 0,5 µmol.
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 µmol in human frontal cortex.
Farmakokinetički/farmakodinamički odnos: pri dozi od 20 mg memantina dnevno, razine u CSL-u odgovaraju ki-vrijednosti (ki = konstanta inhibicije) memantina koja u frontalnom korteksu kod ljudi iznosi 0,5 µmol.
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 μmol in human frontal cortex.
Odnos farmakokinetike/farmakodinamike: pri dozi od 20 mg memantina dnevno razine u CSL-u odgovaraju ki-vrijednosti (ki = konstanta inhibicije) memantina koja u frontalnom korteksu kod ljudi iznosi 0,5 µmol.
Pharmacokinetic/pharmacodynamic relationship: At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki= inhibition constant) of memantine, which is 0.5 μmol in human frontal cortex.
Odnos farmakokinetike/farmakodinamike: pri dozi od 20 mg memantina dnevno, razine u CSL-u odgovaraju ki-vrijednosti (ki = konstanta inhibicije) memantina, koja u frontalnom korteksu kod ljudi iznosi 0,5 µmol.
Pharmacokinetics after use with different nebulisers
Farmakokinetika nakon primjene s različitim atomizatorima
Pharmacokinetics and Drug Metabolism
Farmakokinetika i metabolizam lijeka
Pharmacokinetics has not been specifically studied in the elderly.
Farmakokinetika nije posebno ispitivana u starijih bolesnika.
Pharmacokinetics has not been specifically studied in the hepatic disease patients.
Farmakokinetika nije posebno ispitivana u bolesnika s bolešću jetre.
Pharmacokinetics has not been specifically studied in the renal disease patients.
Farmakokinetika nije posebno ispitivana u bolesnika s bubrežnom bolešću.
Pharmacokinetics have not been specifically studied in different ethnic groups.
Farmakokinetika nije posebno ispitivana u skupinama različite etničke pripadnosti.
Pharmacokinetics in elderly patients have not been investigated.
Farmakokinetika u starijih bolesnika nije ispitivana.
Pharmacokinetics in ILP
Farmakokinetika u postupku izolirane perfuzije uda
Pharmacokinetics in paediatric population
Farmakokinetika u pedijatrijske populacije
Pharmacokinetics in patients aged between 2 to 19 years old with relapsed or refractory ALL or AML following administration of multiple doses of clofarabine by intravenous infusion
Farmakokinetika u bolesnika u dobi između 2 i 19 godina s relapsnom ili refraktornom ALL ili AML nakon primjene višestrukih doza klofarabina intravenskom infuzijom
Pharmacokinetics in pregnancy
Farmakokinetika u trudnoći
Pharmacokinetics in special patient groups Elderly:
Farmakokinetika u posebnim skupinama bolesnika Stariji:
Pharmacokinetics in special patient groups Gender
Farmakokinetika u posebnim skupinama bolesnika Spol
Pharmacokinetics in special patient populations
Farmakokinetika u posebnih populacija bolesnika
Pharmacokinetics in special patient populations
Farmakokinetika u posebnim skupinama bolesnika
Pharmacokinetics in special populations
Farmakokinetika kod posebnih populacija.
Pharmacokinetics in special populations e.g. elderly/renal impairment etc.
Farmakokinetika u posebnim populacijama, npr. starijim bolesnicima/s bubrežnim oštećenjem itd.
Pharmacokinetics in special populations:
Farmakokinetička svojstva u posebnim populacijskim skupinama:
Pharmacokinetics in the paediatric population have not been studied.
Farmakokinetika u pedijatrijskoj populaciji nije ispitana.
Pharmacokinetics observed in multiple sclerosis patients were consistent with those seen in healthy subjects.
Farmakokinetika opažena u bolesnika s multiplom sklerozom bila je dosljedna farmkokinetici opaženoj kod zdravih ispitanika.
Pharmacokinetics observed in patients with rheumatoid arthritis were consistent with those seen in healthy subjects.
Farmakokinetika zabilježena u bolesnika s reumatoidnim artritisom bila je u skladu s onima u zdravih ispitanika.
Pharmacokinetics of 5-ALA in patients with renal or liver impairment has not been investigated.
Farmakokinetika 5-ALA u bolesnika s oštećenjem funkcije jetre ili bubrega nije ispitana.
Pharmacokinetics of asfotase alfa were evaluated in a 1-month, multicenter, open-label, dose- escalating, study in adults with hypophosphatasia.
Farmakokinetika asfotaze alfa procijenjena je u 1-mjesečnom, multicentričnom ispitivanju otvorenog tipa s povećanjem doze u odraslih osoba s hipofosfatazijom.
pharmacokinetics of atazanavir was
U prethodnim ispitivanjima, rifabutin
Pharmacokinetics of cobicistat have not been fully evaluated in hepatitis B and/or C virus co-infected subjects.
Farmakokinetika kobicistata nije potpuno procijenjena u ispitanika istovremeno zaraženih virusom hepatitisa B i/ili C.
Pharmacokinetics of Cuprymina was investigated in mice.
Farmakokinetika Cuprymina je istraživana u miševa.
Pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir have not been evaluated in the elderly (over 65 years).
Farmakokinetika elvitegravira, kobicistata, emtricitabina i tenofovira nije ispitana u starijih pacijenata (preko 65 godina).
Pharmacokinetics of etravirine (mean ± SD, median)
Farmakokinetika etravirina (srednja vrijednost ± SD, medijan)
Pharmacokinetics of iloprost were investigated in a randomised, crossover study with 27 patients, stable on Ventavis 10 microgram/ml inhaled with I-Neb, following inhalation of single doses of 2.5 or 5 microgram iloprost using the Breelib or the I-Neb AAD nebuliser.
Farmakokinetika iloprosta ispitivana je u randomiziranom križnom ispitivanju na 27 bolesnika stabilnih na lijeku Ventavis 10 mikrograma/ml inhaliranom s I-Neb atomizatorom, nakon inhalacije jednokratnih doza od 2,5 ili 5 mikrograma iloprosta pomoću atomizatora Breelib ili I-Neb AAD.
Pharmacokinetics of indinavir do not appear to be affected by race.
Čini se da rasna pripadnost ne utječe na farmakokinetiku indinavira.
Pharmacokinetics of Lutetium (177Lu) was investigated in rats and mice.
Farmakokinetička svojstva lutecija (177Lu) su ispitivana u štakora i miševa.
Pharmacokinetics of NovoSeven in patients with Glanzmann’s thrombasthenia have not been investigated, but are expected to be similar to the pharmacokinetics in haemophilia A and B patients.
Farmakokinetika lijeka NovoSeven u bolesnika s Glanzmannovom trombastenijom nije ispitivana, no smatra se da je slična farmakokinetici u bolesnika s hemofilijom A i B.
Pharmacokinetics of obinutuzumab in patients with mild creatinine clearance (CrCl 50-89 mL/min, n=464) or moderate (CrCl 30 to 49 mL/min, n=106) renal impairment were similar to those in patients with normal renal function (CrCl  90 mL/min, n=383).
Farmakokinetika obinutuzumaba u bolesnika s blagim klirensom kreatinina [CrCl] 50-89 ml/min, n=464) ili umjerenim (CrCl 30-49 ml/min, n=106) oštećenjem funkcije bubrega bila je slična onoj u bolesnika s normalnom funkcijom bubrega (CrCl  90 ml/min, n=383).
Pharmacokinetics of prasugrel and its inhibition of platelet aggregation are similar in patients with moderate renal impairment (GFR 30 - < 50 ml/min/1.73m2) and healthy subjects.
Farmakokinetika prasugrela i njegova inhibicija agregacije trombocita podjednake su u ispitanika s umjerenim oštećenjem bubrega (brzina glomerularne filtracije 30 < 50 ml/min/1,73m2) i zdravih ispitanika.
Pharmacokinetics of prasugrel and its inhibition of platelet aggregation are similar in patients with moderate renal impairment (GFR 30<50 ml/min/1.73m2) and healthy subjects.
Farmakokinetika prasugrela i njegova inhibicija agregacije trombocita podjednake su u ispitanika s umjerenim oštećenjem bubrega (brzina glomerularne filtracije 30 < 50 ml/min/1,73m2) i zdravih ispitanika.
Pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years.
Farmakokinetika telmisartana ne razlikuje se između starijih osoba i osoba mlađih od 65 godina.
Pharmacokinetics of the combination of ombitasvir 25 mg, paritaprevir 150 mg, and ritonavir 100 mg, with dasabuvir 400 mg were evaluated in subjects with mild (CrCl: 60 to 89 ml/min), moderate (CrCl: 30 to 59 ml/min) and severe (CrCl: 15 to 29 ml/min) renal impairment, relative to subjects with normal renal function.
Farmakokinetika kombinacije ombitasvira u dozi od 25 mg, paritaprevira u dozi od 150 mg i ritonavira u dozi od 100 mg, s dasabuvirom u dozi od 400 mg, ocijenjena je u ispitanika s blagim (CrCl: 60 do 89 ml/min), umjerenim (CrCl: 30 do 59 ml/min) i teškim (CrCl: 15 do 29 ml/min) oštećenjem bubrežne funkcije u odnosu na ispitanike s normalnom funkcijom bubrega.
Pharmacokinetics of the combination of ombitasvir 25 mg, paritaprevir 150 mg, and ritonavir 100 mg, with or without dasabuvir 400 mg were evaluated in subjects with mild (CrCl: 60 to 89 ml/min), moderate (CrCl: 30 to 59 ml/min) and severe (CrCl: 15 to 29 ml/min) renal impairment.
Farmakokinetika kombinacije ombitasvira u dozi od 25 mg, paritaprevira u dozi od 150 mg i ritonavira u dozi od 100 mg, s dasabuvirom u dozi od 400 mg ili bez njega, ocijenjena je u ispitanika s blagim (CrCl: 60 do 89 ml/min), umjerenim (CrCl: 30 do 59 ml/min) i teškim (CrCl: 15 do 29 ml/min) oštećenjem bubrežne funkcije.
Pharmacokinetics of the combination of ombitasvir 25 mg, paritaprevir 200 mg, and ritonavir 100 mg were not evaluated in subjects with mild (Child-Pugh A), moderate (Child-Pugh B) and severe (Child- Pugh C) hepatic impairment.
Farmakokinetika kombinacije ombitasvira u dozi od 25 mg, paritaprevira u dozi od 200 mg i ritonavira u dozi od 100 mg nije ocijenjena u ispitanika s blagim (Child-Pugh stadij A), umjerenim (Child-Pugh stadij B) i teškim (Child-Pugh stadij C) oštećenjem jetrene funkcije.
Pharmacokinetics of the combination of ombitasvir 25 mg, paritaprevir 200 mg, and ritonavir 100 mg, with dasabuvir 400 mg were evaluated in subjects with mild (Child-Pugh A), moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment.
Farmakokinetika kombinacije ombitasvira u dozi od 25 mg, paritaprevira u dozi od 200 mg i ritonavira u dozi od 100 mg s dasabuvirom u dozi od 400 mg ocijenjena je u ispitanika s blagim (Child-Pugh stadij A), umjerenim (Child-Pugh stadij B) i teškim (Child-Pugh stadij C) oštećenjem jetrene funkcije.
Pharmacokinetics of toremifene were investigated in an open study with four parallel groups of ten subjects: normal subjects, patients with impaired (mean AST 57 U/L - mean ALT 76 U/L - mean gamma GT 329 U/L) or activated liver function (mean AST 25 U/L - mean ALT 30 U/L - mean gamma GT 91 U/L - patients treated with antiepileptics) and patients with impaired renal function (creatinine: 176 µmol/L).
Farmakokinetika toremifena ispitivana je u otvorenom ispitivanju s četiri usporedne skupine od deset ispitanica: zdrave ispitanice, bolesnice s oštećenom (prosječna AST 57 U/l - prosječna ALT 76 U/l - prosječna gama GT 329 U/l) ili aktiviranom jetrenom funkcijom (prosječna AST 25 U/l - prosječna ALT 30 U/l - prosječna gama GT 91 U/l - bolesnice liječene antiepilepticima) i bolesnice s oštećenom bubrežnom funkcijom (kreatinin: 176 µmol/l).
Pharmacokinetics of trastuzumab emtansine in patients with mild (creatinine clearance CLcr 60 to 89 mL/min, n = 254) or moderate (CLcr 30 to 59 mL/min, n = 53) renal impairment were similar to those in patients with normal renal function (CLcr  90 mL/min, n = 361).
Farmakokinetika trastuzumab emtanzina u bolesnika s blagim (klirens kreatinina CLcr 60 do 89 ml/min, n = 254) ili umjerenim (CLcr 30 do 59 ml/min, n = 53) oštećenjem bubrežne funkcije bila je slična onoj u bolesnika s normalnom bubrežnom funkcijom (CLcr ≥ 90 ml/min, n = 361).
Pharmacokinetics of vinflunine was not modified for patients 70 ≤ age < 75 years and 75 ≤ age < 80 years.
Farmakokinetika vinflunina nije se promijenila za bolesnike u dobi od 70 do 75 godina i u dobi izmeñu 75 i 80 godina.
Pharmacokinetics were dose proportional and did not change over time.
Farmakokinetika je bila razmjerna dozi i nije se mijenjala s vremenom.
Pharmacokinetics were studied in paediatric patients in 4 clinical studies (BREATHE-3, FUTURE 1, FUTURE-3 and FUTURE-4 see section 5.1).
Farmakokinetika u pedijatrijskih bolesnika ispitivana je u 4 kliničke studije (BREATHE-3, FUTURE 1, FUTURE-3 i FUTURE-4, vidjeti dio 5.1).
pharmacokinetics.
farmakokinetike atazanavira.
Pharmacolo- gically active substance
Farmakološki djelatna tvar
Pharmacological doses of NovoSeven activate factor X directly on the surface of activated platelets, localized to the site of injury, independently of tissue factor.
Farmakološke doze lijeka NovoSeven aktiviraju faktor X izravno na površini aktiviranih trombocita, lokaliziranih na mjestu ozljede, neovisno o tkivnom faktoru.
Pharmacological effects associated with titration and maintenance treatment
Farmakološki učinci povezani s titracijom i dozom održavanja
PHARMACOLOGICAL PROPERTIES
FARMAKOLOŠKA SVOJSATVA
PHARMACOLOGICAL PROPERTIES
FARMAKOLŠKA SVOJSTVA
PHARMACOLOGICAL PROPERTIES
FARMKOLOŠKA SVOJSTVA
PHARMACOLOGICAL PROPERTIES
Vrijeme (minute)
PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group:
FARMAKOLOŠKA SVOJSTVA
Pharmacological studies have demonstrated that granisetron is effective against nausea and vomiting as a result of cytostatic therapy.
Farmakološka ispitivanja dokazala su da je granisetron učinkovit protiv mučnine i povraćanja koji su posljedica liječenja citostaticima.
Pharmacologically active substance
Farmakološki djelatna(e) tvar(i):
Pharmacologically active substance(s)
Farmakološki djelatna tvar
Pharmacotherapeutic group (human normal immunoglobulin): immune sera and immunoglobulins: immunoglobulins, normal human, ATC code: J06BA
Farmakoterapijska skupina (normalni ljudski imunoglobulin): imunoserumi i imunoglobulini: imunoglobulini, normalni ljudski, ATK oznaka: J06BA
Pharmacotherapeutic group - Antivirals for systemic use, nucleoside and nucleotide reverse transcriptase inhibitors, ATC Code: J05AF05.
Farmakoterapijska skupina – Antivirotici za sistemsku primjenu, inhibitori nukleozidne i nukleotidne reverzne transkriptaze, ATK oznaka: J05AF05.
Pharmacotherapeutic group - Antivirals for systemic use, nucleoside and nucleotide reverse transcriptase inhibitors,ATC Code: J05AF05.
Farmakoterapijska skupina – Pripravci za liječenje sustavnih virusnih infekcija, inhibitori nukleozidne i nukleotidne reverzne transkriptaze, ATK oznaka: J05AF05.
Pharmacotherapeutic group : Fast-acting human insulin analogue.
Farmakoterapijska skupina: analog humanog inzulina brzog djelovanja.
Pharmacotherapeutic group :Fast-acting human insulin analogue.
Farmakoterapijska skupina: analog humanog inzulina brzog djelovanja.
Pharmacotherapeutic group: <not yet assigned>, ATC code: <not yet assigned>
Farmakoterapijska skupina: < nije još dodijeljena>, ATK oznaka: <nije još dodijeljena>
Pharmacotherapeutic group: ACE inhibitors, combinations.
Farmakoterapijska grupa: ACE inhibitori, kombinacije.
Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, angiotensin II antagonists, other combinations, ATC code: C09DX01.
Farmakoterapijska skupina: Pripravci koji djeluju na renin-angiotenzinski sustav, antagonisti angiotenzina II, ostale, ATK oznaka: C09DX01.
Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, renin inhibitors, ATC code: C09XA53
Farmakoterapijska skupina: lijekovi koji djeluju na sustav renin-angiotenzin; inhibitor renina, ATK oznaka: C09XA53
Pharmacotherapeutic group: Agents acting on the renin-angiotensin system; renin inhibitor (aliskiren) combinations with diuretics (hydrochlorothiazide), ATC code: C09XA52
Farmakoterapijska skupina: lijekovi koji djeluju na sustav renin-angiotenzin; kombinacija inhibitora renina (aliskiren) s diureticima (hidroklorotiazid), ATK oznaka: C09XA52.
Pharmacotherapeutic group: all other therapeutic products, antidotes, ATC code: V03AB37 Mechanism of action
Farmakoterapijska skupina: ostali terapijski pripravci, antidoti, ATK oznaka: V03AB37 Mehanizam djelovanja
Pharmacotherapeutic group: All other therapeutic products, ATC code: V03AX03 Mechanism of action and pharmacodynamic effects
Farmakoterapijska skupina: svi drugi terapijski pripravci, ATK oznaka: V03AX03 Mehanizam djelovanja i farmakodinamički učinci
Pharmacotherapeutic group: Amino acids and derivatives; ATC code: A16AA05 Mechanism of action
Farmakoterapijska skupina: Aminokiseline i derivati; ATK oznaka: A16AA05 Mehanizam djelovanja
Pharmacotherapeutic group: Anaesthetics, amides, ATC code: NO1BB20 Mechanism of action
Farmakoterapijska skupina: Anestetici, amidi, ATK oznaka: N01BB20 Mehanizam djelovanja
Pharmacotherapeutic group: Anaesthetics, other local anaesthetics, ATC code: N01BX04 Mechanism of action
Farmakoterapijska skupina: anestetici, drugi lokalni anestetici, ATK oznaka: N01BX04 Mehanizam djelovanja
Pharmacotherapeutic group: Analgesics, opioids, ATC code: N02AB03 Mechanism of action
Farmakoterapijska skupina: Analgetici, opioidi, ATK oznaka: N02AB03 Mehanizam djelovanja
Pharmacotherapeutic group: Analgesics, other analgesics and antipyretics, ATC code: N02BG08 Mechanism of action
Farmakoterapijska skupina: analgetici, drugi analgetici i antipiretici, ATK oznaka: N02BG08 Mehanizam djelovanja
Pharmacotherapeutic group: analgesics; opioids;; ATC code N02AB03.
Farmakoterapijska skupina: analgetici, opioidi; ATK oznaka N02AB03.
Pharmacotherapeutic group: Angiotensin II antagonists and diuretics, ATC code:C09DA07.
Farmakoterapijska skupina: antagonisti angiotenzina II s diureticima, ATK oznaka: C09DA07.
Pharmacotherapeutic Group: Angiotensin II Antagonists, plain ATC Code: C09CA07.
Farmakoterapijska skupina: Antagonisti angiotenzina II, čisti, ATK oznaka: C09CA07.
Pharmacotherapeutic group: angiotensin II antagonists, plain, telmisartan ATCvet code: QC09CA07
Farmakoterapijska skupina: antagonisti angiotenzina II, jednokomponentni proizvodi, telmisartan ATCvet kod: QC09CA07
Pharmacotherapeutic group: angiotensin-II antagonists, combinations ATC code: C09D A04
Farmakoterapijska skupina: antagonisti angiotenzina II, kombinacije ATK oznaka: C09D A04
Pharmacotherapeutic group: angiotensin-II antagonists, combinations ATC code: C09DA04.
Farmakoterapijska skupina: antagonisti angiotenzina II, kombinacije ATK oznaka: C09D A04
Pharmacotherapeutic group: Anthelmintics, benzimidazole and related substances – fenbendazole.
Farmakoterapijska skupina: anthelmintici, benzimidazol i slične tvari - fenbendazol.
Pharmacotherapeutic group: Anti epileptics, other anti-epileptics ATC code: N03AX16 The active substance, pregabalin, is a gamma-aminobutyric acid analogue
Farmakoterapijska skupina: Antiepileptici, ostali antiepileptici; ATK oznaka: N03AX16 Djelatna tvar je pregabalin, analog gama-aminomaslačne kiseline
Pharmacotherapeutic group: Anti-epileptics, other anti-epileptics ATC code: N03AX16
Farmakoterapijska skupina: Antiepileptici, ostali antiepileptici; ATK oznaka: N03AX16 Djelatna tvar je pregabalin, analog gama-aminomaslačne kiseline
Pharmacotherapeutic group: Anti-epileptics, other anti-epileptics ATC code: N03AX16 The active substance, pregabalin, is a gamma-aminobutyric acid analogue
Farmakoterapijska skupina: Antiepileptici, ostali antiepileptici; ATK oznaka: N03AX16 Djelatna tvar je pregabalin, analog gama-aminomaslačne kiseline
Pharmacotherapeutic group: Anti-epileptics, other anti-epileptics ATC code: N03AX16 The active substance, pregabalin, is a gamma-aminobutyric acid analogue [(S)-
Farmakoterapijska skupina: Antiepileptici, ostali antiepileptici; ATK oznaka: N03AX16 Djelatna tvar je pregabalin, analog gama-aminomaslačne kiseline
Pharmacotherapeutic group: Anti-epileptics, other anti-epileptics, ATC code: N03AX16.
Farmakoterapijska skupina: Antiepileptici, ostali antiepileptici; ATK oznaka: N03AX16 Djelatna tvar je pregabalin, analog gama-aminomaslačne kiseline
Pharmacotherapeutic group: Anti-epileptics, other anti-epileptics; ATC code: N03AX16.
Farmakoterapijska skupina: Antiepileptici, ostali antiepileptici; ATK oznaka: N03AX16.
Pharmacotherapeutic group: Anti-hypertensives, other anti-hypertensives, ATC code: C02KX02
Farmakoterapijska skupina: Antihipertenzivi, ostali antihipertenzivi: ATK oznaka: C02KX02
Pharmacotherapeutic group: Anti-inflammatory and anti-rheumatic products, non-steroids (oxicams) ATCvet code: QM01AC06
Farmakoterapijska skupina: protuupalni i protureumatski proizvodi, nesteroidi (oksikami) ATKvet kod: QM01AC06
Pharmacotherapeutic group: Anti-inflammatory and anti-rheumatic products, non-steroids (oxicams), ATC vet code: QM01AC06
Farmakoterapijska skupina: antiinflamatorni i antireumatski proizvodi, nesteroidi (oksikami) ATC vet kod: QM01AC06
Pharmacotherapeutic group: Anti-inflammatory and anti-rheumatic products, non-steroids, coxibs.
Farmakoterapijska grupa: Protuupalni i antireumatski lijekovi, nesteroidi, koksibi.
Pharmacotherapeutic Group: Anti-inflammatory and antirheumatic products, non-steroids (oxicams).
Farmakoterapijska skupina: antiinflamatorni i antireumatski proizvodi, nesteroidi (oksikami).
Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids, coxibs.
Farmakoterapijska grupa: protuupalni i antireumatski lijekovi, nesteroidi, koksibi.
Pharmacotherapeutic group: Anti-Parkinson-Drugs, Monoamine oxidase -B inhibitors, ATC code: N04BD02
Farmakoterapijska skupina: Antiparkinsonici, inhibitori monoaminooksidaze B, ATK oznaka: N04BD02
Pharmacotherapeutic group: antianemic, ATC code: B03XA01 Mechanism of action
Farmakoterapijska skupina: antianemici, ATK oznaka: B03XA01 Mehanizam djelovanja
Pharmacotherapeutic group: antibacterials for systemic use, glycopeptide antibacterials, ATC code: J01XA04.
Farmakoterapijska skupina: antibakterijski lijekovi za sistemsku primjenu, glikopeptidni antibakterijski lijekovi,ATK oznaka: J01XA04.
Pharmacotherapeutic group: antibacterials for systemic use, macrolides, lincosamides and streptogramins, ATC Code: J01FA15.
Farmakoterapijska skupina: antibiotici za sustavnu primjenu, makrolidi, linkozamidi i streptogramini, ATK oznaka: J01FA15.
Pharmacotherapeutic group: antibacterials for systemic use, macrolides.
Farmakoterapijska grupa: antibiotici za sustavnu primjenu, makrolid.
Pharmacotherapeutic group: Antibacterials for systemic use, other cephalosporins, ATC code: J01DI02
Farmakoterapijska skupina: Lijekovi za liječenje bakterijskih infekcija za sustavnu primjenu, ostali cefalosporini, ATK oznaka: J01DI02
Pharmacotherapeutic group: Antibacterials for systemic use, third-generation cephalosporins.
Farmakoterapijska grupa: Antibakterijska sredstva za sistemsku upotrebu , cefalosporini treće generacije.
Pharmacotherapeutic group: Antibiotics and chemotherapeutics for dermatological use, Antibiotics for topical use.
Farmakoterapijska skupina: Antibiotici i kemoterapeutici - dermatici, antibiotici za topikalnu primjenu.